Carlyle.
The realisation machine among global PE firms in India: SBI Cards' ~$3bn multi-tranche cash-out (2020-22), PNB Housing Finance's ₹7,592 Cr staged full exit (Jul 2024-May 2025) and Hexaware's $5.34bn IPO debut (Feb 2025, ~74% still held) sit against a $300M dedicated India side fund and an August 2026 Piramal Pharma block-sale reversal that reads as caution, not conviction.
GW GP Score
Carlyle entered India in 2005 and has deployed roughly $8bn since (Bloomberg, Mar 2025), almost entirely through its pan-Asia buyout funds rather than a standalone India vehicle — the $300M side fund disclosed alongside the $2.85bn Carlyle Asia Partners VI, with IFC proposing up to $60M, is its first dedicated India pool. The realisation record built on that borrowed capacity is genuine: SBI Cards returned roughly $3bn across the 2020 IPO and four block trades by April 2022, and PNB Housing Finance was fully sold down for ₹7,592 Cr across three 2024-25 tranches, after an earlier and much larger 2021 attempt to buy control at ₹390/share was halted by SEBI for inadequate independent valuation and later terminated. Hexaware's February 2025 listing added a third cash event: an OFS at up to 1.8x cost against a $5.34bn market cap, with roughly three-quarters of the company still held. What the record doesn't yet show is fresh conviction — the August 2026 decision to reverse a planned 6-10% Piramal Pharma block sale, after March 2025 filings had already shown the stake down to 18% from 20%, reads as a stalled pipeline sitting behind a still-small dedicated fund.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Piramal Pharma's actual stake: 18% per Mar 2025 filings vs. a report describing the Aug 2026 cancellation as preserving the '20% holding' — reconcile at the next disclosed shareholding pattern.
India side fund: targeted at $300M with IFC's $60M proposed (disclosed Nov 2025) — no confirmed first close as of Sep 2026.
The $300M India side fund is a fraction of India-dedicated peers' latest vehicles (ChrysCapital's $2.2bn Fund X, Kedaara's Fund IV); most Carlyle India capital still competes for allocation inside the $2.85bn pan-Asia CAP VI.
Computed from current dossier sources; analyst override pending.
Three separately priced, verifiable cash-outs — SBI Cards, PNB Housing, Hexaware's OFS slice — make the realisation record real rather than self-reported. Capital discipline holds the score down: a blocked 2021 control bid and a reversed 2026 block sale both cut against a franchise still running India through borrowed pan-Asia capacity.
Graded underPrivate equity rubric v1.0→Hexaware's ~74% retained at a $5.34bn cap, Piramal's CDMO franchise and the Highway-Roop platform carry real earnings; the 2021 PNB Housing episode is the control-rights scar
SBI Cards (~$3bn) and PNB Housing's ₹7,592 Cr staged exit are the desk's cleanest global-firm India cash-back stories; Hexaware's OFS adds a third, still-majority-held leg
Genuine platform-building (Highway+Roop's 12-plant merger, SeQuent-Viyash's ₹8,000 Cr consolidation) rather than pure multiple arbitrage
A $300M India side fund next to the $2.85bn pan-Asia CAP VI is thin; the 2021 blocked control bid and the 2026 cancelled block sale are both discipline misses on the record
Jain and Bharadwaj have run India leadership without a reported senior exit since Nov 2021; backed by Carlyle's $485bn global platform (Q2 2026 AUM)
Asset quality & control 25% · Exit realisation 30% · Value creation 15% · Capital discipline 15% · Franchise stability 15% — the five contributions above sum to 74. Raw scores compare within private equity; across cohorts compare the tier. See the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Hexaware Technologies liquidity clears with credible OFS/block-sale evidence.
India side fund: targeted at $300M with IFC's $60M proposed (disclosed Nov 2025) — no confirmed first close as of Sep 2026.
Piramal Pharma's actual stake: 18% per Mar 2025 filings vs. a report describing the Aug 2026 cancellation as preserving the '20% holding' — reconcile at the next disclosed shareholding pattern.
Carlyle's India book proves itself in cash, not just marks: SBI Cards, PNB Housing and Hexaware's OFS slice are three separate, third-party-priced realisations inside five years. Ask the harder question before the new $300M side fund closes: why does a firm with an $8bn deployment record since 2005 still run India through borrowed capacity in a pan-Asia vehicle rather than its own flagship?
The $300M India side fund is a fraction of India-dedicated peers' latest vehicles (ChrysCapital's $2.2bn Fund X, Kedaara's Fund IV); most Carlyle India capital still competes for allocation inside the $2.85bn pan-Asia CAP VI.
Piramal Pharma's actual stake: 18% per Mar 2025 filings vs. a report describing the Aug 2026 cancellation as preserving the '20% holding' — reconcile at the next disclosed shareholding pattern.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
~$8bn deployed in India since 2005, ~44+ investments (Bloomberg, Mar 2025) across 3 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Carlyle Asia Partners VI + India side fund | 2023 / raisingTrough window | $2.85bn (CAP VI) + $300M targeted (India sleeve) | Control & growth buyouts | India sleeve disclosed Nov 2025; IFC has proposed up to $60M; no confirmed first close as of Sep 2026 (E) |
| Carlyle Asia Partners V | 2018Expansion | $6.55bn | Control & growth buyouts | Vintage behind the 2020 Piramal Pharma and 2023 VLCC deployments |
| Carlyle Asia Partners III/IV | 2008-2013Foundation era | $2.55bn / $3.9bn | Control & growth buyouts | Vintage behind SBI Cards (2017), Global Health/Medanta (2013) and PNB Housing Finance's original stake |
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle is still in market or not publicly closed.
Next liquidityHexaware Technologies · Global Health (Medanta)
2 visible exit events since Jul 2024.
Latest vehicle is still in market or not publicly closed.
4 up / 3 flat / 0 down tracked signals.
No senior departure flagged in key people.
4 up / 3 flat / 0 down
2 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Best entry conditions of the cycle
Rational growth vintages
Pre-unicorn pricing; discovery-cost entries
IT services/BPO, not dev-tools — the taxonomy's nearest fit. IPO'd Feb 2025 at a ₹46,340 Cr ($5.34bn) market cap; Carlyle sold ~21% via OFS at up to 1.8x its ₹385.35 average cost and retains ~74%
Sold part of a 25.67% stake in the Nov 2022 IPO OFS; residual holding untraced in public filings since (E)
At least one cited source is dated 2026.
2 visible events tracked.
7 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 3 · -1
Peer median 2 · +0
Peer median 89 · -5
Peer median 38 · +19
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
The latest vehicle is raising, unclosed or stale against the current deployment cycle.
Current · At least one cited source is dated 2026.
India side fund: targeted at $300M with IFC's $60M proposed (disclosed Nov 2025) — no confirmed first close as of Sep 2026.
Track first/final close, LP quality, target-vs-close delta and mandate shift.
India side fund: targeted at $300M with IFC's $60M proposed (disclosed Nov 2025) — no confirmed first close as of Sep 2026.
Hexaware Technologies: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Portfolio data, Performance proxy.
15 total sources · 27% primary
At least one cited source is dated 2026.
Carlyle: Edelweiss brings in Carlyle as strategic majority investor in Nido (Feb 2026)
Upgrade Portfolio data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
44+ investments and ~$8bn deployed since 2005 (Carlyle; Bloomberg, Mar 2025). 7 tracked below across the live book.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Hexaware Technologies | SaaS & Dev Tools | 2021 | Buyout from Baring Private Equity Asia (~$3bn EV) via CA Magnum Holdings | Public | ▲ | IT services/BPO, not dev-tools — the taxonomy's nearest fit. IPO'd Feb 2025 at a ₹46,340 Cr ($5.34bn) market cap; Carlyle sold ~21% via OFS at up to 1.8x its ₹385.35 average cost and retains ~74% |
| Piramal Pharma | Healthcare | 2020 | 20% strategic growth (₹3,523 Cr / ~$490M) via CA Alchemy Investments | Public | → | Down to 18% by Mar 2025; a planned 6-10% block sale (₹1,750-2,700 Cr, Motilal Oswal-mandated) was reported Jul 2025, then cancelled Aug 2026 with no reason given — sources conflict on whether the stake is back at 20% or still 18% |
| SeQuent Scientific / Viyash Scientific | Healthcare | 2020 | 74% control (₹1,500+ Cr) via CA Harbor Investments | Public | ▲ | ₹8,000 Cr merger with Viyash Life Sciences (announced Sep 2024, NCLT-cleared, effective late 2025) built India's largest animal-health platform; Carlyle holds 61.3% of the combined entity |
| Global Health (Medanta) | Healthcare | 2013 | 26% minority (₹960 Cr) via Anant Investments/Carlyle Asia Partners III | Public | → | Sold part of a 25.67% stake in the Nov 2022 IPO OFS; residual holding untraced in public filings since (E) |
| VLCC | Consumer & Commerce | 2023 | 65-70% control (₹2,255-2,460 Cr / ~$300M) via Carlyle Asia Partners | Private | → | Primary infusion plus a secondary purchase from the founding Luthra family, who retain a minority stake |
| Highway Industries + Roop Automotives | Logistics & Infra | 2025 | Controlling stake (undisclosed) via Carlyle Asia Partners | Public | ▲ | Forged/precision auto-components manufacturer, not infrastructure — the taxonomy's nearest fit. Combined platform runs 12 plants and 14 warehouses across 17 countries |
| Nido Home Finance (ex-Edelweiss) | Fintech | 2026 | 45% + ₹1,500 Cr primary infusion (₹2,100 Cr / $232M total) via Carlyle Asia Partners | Private | ▲ | Post-deal, Carlyle affiliates hold ~73% of the ₹4,804 Cr-AUM housing financier; joins Blackstone and SMFG in India housing-finance bets |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
The 2025-26 cheques run one playbook regardless of sector: buy control or governance rights in a cash-generative business and consolidate it into something bigger. Highway Industries and Roop Automotives became one 12-plant global auto-parts platform in Feb 2025; SeQuent Scientific merged into Viyash Life Sciences for a ₹8,000 Cr animal-health platform; Nido Home Finance took a ₹2,100 Cr majority investment in Feb 2026. None is a minority growth bet.
Takes Carlyle affiliates to ~73% of the housing financier
NCLT-cleared Sep 2024, effective late 2025; Carlyle holds 61.3% of the combined animal-health platform
Combined into a 12-plant global auto-components platform; Mohit Oswal (Roop) named Non-Executive Chairperson
Realisation · are LPs getting paid?
SBI Cards remains the house's proof of concept: a 26% stake bought from GE Capital in 2017 returned roughly $3bn across the March 2020 IPO and four block trades through April 2022. PNB Housing Finance took longer and survived more — the original stake outlasted a 2021 attempt to buy control at ₹390/share that SEBI blocked for inadequate independent valuation, then wound down across three 2024-25 tranches for ₹7,592 Cr and a complete exit. Hexaware's Feb 2025 IPO added a third, partial leg: ~21% sold at up to 1.8x cost, ~74% retained. Metropolis Healthcare (2015 entry, fully exited by Apr 2020) rounds out a genuine multi-cycle record. What breaks the streak is Piramal Pharma: a planned 6-10% block sale reported in July 2025 was reversed in August 2026 with no reason disclosed — the one 2025-26 realisation that didn't happen.
CA Magnum Holdings sold ~21% via OFS at ₹674-708/share; day-one close of ₹762.55 valued the company at ₹46,340 Cr ($5.34bn), ~1.8x Carlyle's ₹385.35 average cost. Carlyle retains ~74%.
Final 10.44% sold for ₹2,712.97 Cr at ₹1,000.20/share across 8 tranches via Quality Investment Holdings PCC: complete exit, after ₹2,578 Cr (Jul 2024, 12.8%) and ₹2,301.58 Cr (Nov 2024, 9.43%) — ₹7,592 Cr realised in total.
2017 entry via a 26% stake bought from GE Capital; exited across the 2020 IPO plus 4 block trades by Apr 2022
Jul 2024-May 2025, after surviving a SEBI-blocked 2021 control bid
Feb 2025 OFS on ~21%; ~74% still held
Aug 2026 reversal of a planned 6-10% sell-down first reported Jul 2025
No fund-level DPI or TVPI is public for Carlyle's India exposure, which sits inside pan-Asia vehicles rather than a standalone fund. GW read: three independently priced cash events — SBI Cards, PNB Housing, Hexaware's OFS slice — put the realisation record ahead of most global-firm India franchises on hard rupee and dollar terms; the open question is whether a $300M dedicated side fund is enough vehicle for the ambitions Carlyle states publicly, in wealth management, housing finance and auto components. E.
What they're doing
Control or governance-grade stakes in regulator-adjacent, cash-generative businesses — financial services, pharma/healthcare, auto components — deployed mostly through pan-Asia vehicles rather than an India-only fund until the 2025 side fund.
Sell into strength once a listing or strategic buyer appears: SBI Cards' block-trade cadence and PNB Housing's three-tranche exit are the template; Hexaware's IPO reruns it at $5bn+ scale.
Platform consolidation as a value-creation lever: Highway+Roop and SeQuent-Viyash both merge two owned or acquired assets into one larger entity rather than holding them separately.
New sector reach into wealth/asset management (stated ambition, Mar 2025) and housing finance (Nido, Feb 2026) as Indian households shift savings toward financial assets.
What can break
The $300M India side fund is a fraction of India-dedicated peers' latest vehicles (ChrysCapital's $2.2bn Fund X, Kedaara's Fund IV); most Carlyle India capital still competes for allocation inside the $2.85bn pan-Asia CAP VI.
The 2021 PNB Housing preferential-issue attempt — blocked by SEBI for inadequate independent valuation — is a governance scar on any future control bid for a listed target.
Healthcare/pharma concentration (Piramal, Viyash, Medanta) ties roughly a third of the book to one regulatory and pricing cycle.
The cancelled Piramal block sale leaves the market unable to tell whether Carlyle is holding for a better price or has lost an exit route; either reading is a live unknown.
Piramal Pharma's actual stake: 18% per Mar 2025 filings vs. a report describing the Aug 2026 cancellation as preserving the '20% holding' — reconcile at the next disclosed shareholding pattern.
India side fund: targeted at $300M with IFC's $60M proposed (disclosed Nov 2025) — no confirmed first close as of Sep 2026.
Global Health/Medanta residual stake: untraced in public filings since the Nov 2022 IPO OFS (pre-IPO holding 25.67%) — verify at next shareholding disclosure.
Carlyle's stated India wealth/asset-management platform ambition (Mar 2025): no named target or deal yet.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
Carlyle's India book proves itself in cash, not just marks: SBI Cards, PNB Housing and Hexaware's OFS slice are three separate, third-party-priced realisations inside five years. Ask the harder question before the new $300M side fund closes: why does a firm with an $8bn deployment record since 2005 still run India through borrowed capacity in a pan-Asia vehicle rather than its own flagship?
The Highway-Roop and SeQuent-Viyash playbook — buy two adjacent assets, merge them into one platform with scale — is a template worth copying in auto components and pharma manufacturing. Carlyle's healthcare weight (Piramal, Viyash, Medanta) also means it is bidding against you for any hospital or CDMO asset that comes to market.
The cancelled Piramal Pharma block sale is worth tracking as a market-conditions tell, not just a company-specific one: a global PE major choosing to hold rather than sell into a rupee-listed pharma stock in August 2026 says something about where secondary pricing for pharma services sits right now.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.